RLT Manufacturing

Each production route for Ac-225 has its own set of unique challenges. Building on years of research knowledge and isotope production experience, NorthStar Medical Radioisotopes has embarked on a solution to create a domestic source of this powerful alpha-emitting radiopharmaceutical therapy. NorthStar, leveraging prior experience, has chosen the electron accelerator production method as it provides the best option for sustainable, scalable, and reliable production of n.c.a. Ac-225.

Major advances in radiopharmaceutical therapy show significant promise for the treatment of cancer and other serious diseases. For these advances to positively impact patient healthcare, they will require a significant increase in isotope production that is not dependent on aging nuclear reactors, but instead through development of a modern, robust, and commercial scale supply chain.

The use of electron accelerators provides a path for the commercial scale production of high-quality isotopes, continuing NorthStar’s approach of producing medically significant radioisotopes with minimal radioactive waste. Simply put, the reliable, scalable production of n.c.a. Ac-225 has immense potential to accelerate treatment options for millions of patients with cancer and other serious diseases.

Located adjacent to the dedicated Ac-225 production facility on its campus in Beloit, Wis., is a 30,000 sq. ft. facility that houses two electron accelerators where NorthStar is routinely producing high activity, high specific activity and high purity copper-67 (Cu-67) for Clarity Pharmaceuticals’ ongoing clinical programs. Targeted Copper Theranostics (TCTs) are the next-generation disruptive platform in radiopharmaceuticals that employ the radioisotopes copper-64 (Cu-64) for diagnosis and copper-67 (Cu-67) for therapy. TCTs deliver a compelling combination of a high accuracy and high precision option in the treatment in a range of cancers. TCTs provide a scalable, dependable, and, importantly, an environmentally friendly way to expand radiopharmaceuticals into the global oncology market.